Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) shares shot up 2.1% on Monday . The stock traded as high as GBX 1.60 ($0.02) and last traded at GBX 1.60 ($0.02). 6,130,743 shares traded hands during trading, a decline of 54% from the average session volume of 13,221,415 shares. The stock had previously closed at GBX 1.57 ($0.02).
Hemogenyx Pharmaceuticals Stock Performance
The company has a current ratio of 4.07, a quick ratio of 6.72 and a debt-to-equity ratio of 89.95. The company has a market capitalization of £21.44 million, a price-to-earnings ratio of -160.00 and a beta of 3.06. The stock’s fifty day simple moving average is GBX 1.73 and its 200-day simple moving average is GBX 2.26.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Read More
- Five stocks we like better than Hemogenyx Pharmaceuticals
- What is the Hang Seng index?
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Value Stocks You Can Buy Before They Become Big
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
